Background: Loss of the Y chromosome (LOY) is the most frequent somatic alteration in male cancers and has recently been linked to immune evasion, metabolic reprogramming and prognosis. Because the Y chromosome encodes transcriptional and epigenetic regulators, such as UTY and KDM5D, LOY is assumed to act through dysregulation of autosomal gene expression. We asked whether LOY produces a transcriptional signature in clear cell renal cell carcinoma (ccRCC), where about 40% of male tumors lose the Y chromosome. Methods: Here, we inferred Y chromosome status from RNA-sequencing of male ccRCC in TCGA-KIRC (n = 289) and CPTAC-ccRCC (n = 114), in 32 tumors from an autochthonous Vhl/Trp53/Rb1-deficient mouse model, and in five isogenic Y-deficient and five Y-retaining clones of the 786-O cell line. Differential expression was tested with Wilcoxon rank-sum tests on age- and purity-adjusted residuals combined by Stouffer meta-analysis (human cohorts) or with DESeq2 (mouse, cell clones), followed by gene set enrichment analysis. Pseudoautosomal genes, present on both sex chromosomes, served as internal controls for a halving of gene dosage. Results: In all three settings, transcriptional changes were confined to the expected dosage effects of male-specific Y and pseudoautosomal genes. No autosomal gene reached the significance level of the non-compensated pseudoautosomal genes in human ccRCC, 14 autosomal genes were altered in the mouse model and 40 in the isogenic 786-O clones, none shared across settings. Gene set enrichment analysis revealed a modest, reproducible upregulation of cell division, ribosome biogenesis and DNA repair pathways shared between human and murine ccRCC. A meta-analysis across 27 male TCGA cancer entities (1,710 LOY, 2,988 Y-retaining tumors) recovered the same pattern with no autosomal gene showing a consistent large effect, and the same cell division, ribosome biogenesis and DNA repair pathways were modestly upregulated. Cancer/testis antigen expression was elevated in LOY tumors of several entities, most notably stomach adenocarcinoma, but not ccRCC. Conclusions: Beyond direct gene dosage, LOY leaves the transcriptome of ccRCC, and of most other cancer entities, essentially unchanged. Y-encoded genes are therefore unlikely to drive cancer through direct transcriptional regulation of autosomal genes, directing attention to non-transcriptional effects of LOY.